Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADAP 
Adaptimmune Therapeutics Plc (ADAP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: ADAP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1.45
1 Year Target Price $1.45
| 3 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.67% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 71.56M USD | Price to earnings Ratio - | 1Y Target Price 1.45 |
Price to earnings Ratio - | 1Y Target Price 1.45 | ||
Volume (30-day avg) 9 | Beta 2.25 | 52 Weeks Range 0.20 - 1.48 | Updated Date 07/17/2025 |
52 Weeks Range 0.20 - 1.48 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -38.91% | Operating Margin (TTM) -604.96% |
Management Effectiveness
Return on Assets (TTM) -14.19% | Return on Equity (TTM) -275.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 63622497 | Price to Sales(TTM) 0.4 |
Enterprise Value 63622497 | Price to Sales(TTM) 0.4 | ||
Enterprise Value to Revenue 0.35 | Enterprise Value to EBITDA -1.71 | Shares Outstanding 265052000 | Shares Floating 1046757646 |
Shares Outstanding 265052000 | Shares Floating 1046757646 | ||
Percent Insiders 0.63 | Percent Institutions 44.16 |
Upturn AI SWOT
Adaptimmune Therapeutics Plc
Company Overview
History and Background
Adaptimmune Therapeutics Plc, founded in 2008, focuses on developing T-cell therapies for cancer. It originated from research at Oxford University. Significant milestones include clinical trial advancements and regulatory approvals in 2024.
Core Business Areas
- T-cell Therapy Development: Develops engineered T-cell therapies (TCR T-cells) designed to target and destroy cancer cells.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its T-cell therapies across various cancer types.
- Manufacturing and Supply: Focuses on the manufacturing and supply of its T-cell therapy products to support clinical trials and commercialization.
Leadership and Structure
The leadership team comprises experienced executives in the biotechnology industry. The organizational structure is focused on research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Afami-cel (Afamitresgene autoleucel) (TCR T-cell therapy for synovial sarcoma): FDA-approved treatment for advanced synovial sarcoma. Competitors include conventional chemotherapy and radiation therapies, as well as other emerging immunotherapies, cell therapies and TIL (tumor-infiltrating lymphocyte) therapies from companies like Iovance. No definitive market share data is currently available, as it is a new therapy.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advancements in cancer treatment and a growing demand for personalized therapies.
Positioning
Adaptimmune is a key player in the TCR T-cell therapy field, specializing in targeting solid tumors. Its competitive advantage lies in its proprietary TCR engineering platform.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy is estimated at billions of dollars annually. Adaptimmune is positioned to capture a portion of this market through its novel T-cell therapies.
Upturn SWOT Analysis
Strengths
- Proprietary TCR engineering platform
- FDA approval for Afami-cel (TCR T-cell therapy for synovial sarcoma)
- Strong research and development capabilities
- Experienced management team
Weaknesses
- High research and development costs
- Dependence on regulatory approvals
- Limited number of approved products
- Manufacturing complexity
Opportunities
- Expansion of T-cell therapy pipeline to other cancer types
- Partnerships with pharmaceutical companies
- Advancements in TCR engineering technology
- Increasing demand for personalized cancer therapies
Threats
- Competition from other immunotherapy companies
- Regulatory hurdles
- Clinical trial failures
- Patent disputes
Competitors and Market Share
Key Competitors
- IOVA
- NK
- CRSP
Competitive Landscape
Adaptimmune has a focused approach with their engineered T cell receptor while other companies take different novel approaches to cancer treatments. Adaptimmune's is focused on solid tumors.
Growth Trajectory and Initiatives
Historical Growth: Focus on clinical trial results and securing FDA approval.
Future Projections: Projected growth is driven by commercialization of approved products and expansion of the pipeline. Analyst estimates will need to be accessed to input the numerical projections.
Recent Initiatives: Initiatives focused on expanding clinical trials and seeking regulatory approvals for new indications.
Summary
Adaptimmune Therapeutics Plc is focused on T-cell therapies for cancer. The company recently acquired FDA approval for its lead TCR T-cell therapy, Afami-cel. However, it also faces challenges related to high R&D costs and competition. Future success depends on expanding its product pipeline and commercializing the current treatments and other new novel therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- FDA Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adaptimmune Therapeutics Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-05-06 | CEO & Director Mr. Adrian G. Rawcliffe | ||
Sector Healthcare | Industry Biotechnology | Full time employees 506 | Website https://www.adaptimmune.com |
Full time employees 506 | Website https://www.adaptimmune.com | ||
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.